Monitor future DoD and BARDA contract modifications for BioThrax and CYFENDUS, as these government orders represent a recurring revenue stream. The company's reliance on government contracts for its anthrax franchise is reinforced by this award.
Drugs in focus
EBS drug pipeline →BioThrax
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed since 1970.
- Next catalyst
- None dated
What to watchBioThrax is a mature, approved product with no pending FDA catalyst. The stock's next binary event is the Q4 2026 earnings report (likely Feb 2027), where the key question is whether Anthrax MCM revenue stabilizes after the Q3 miss and whether the CYFENDUS transition cannibalizes BioThrax further. Watch for DoD contract renewals on the $21.5M BioThrax delivery order (option periods for 2027-2028).
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $5.85entry
- T+1 · 11d ago +3.59%α +3.28% · $6.06
- T+5 · 5d ago +0.68%α −2.61% · $5.89
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Emergent BioSolutions announced a $22.3 million delivery order modification from the U.S. Department of War to supply BioThrax (anthrax vaccine) to all branches of the U.S. military. The first delivery of approximately $7.4 million begins in 2026, with remaining deliveries in 2027. This is a routine government contract modification under an existing IDIQ contract, representing incremental revenue of about 6.8% of the company's $330M market cap.
Key Facts
- Emergent received a modification exercising an option period under an existing delivery order valued at up to $22.3 million to supply BioThrax to the U.S. Department of War.
- First delivery valued at approximately $7.4 million will begin in 2026; remaining deliveries expected in 2027.
- The order is under the existing IDIQ contract (W911SR24D0001) led by PME CBRND in collaboration with the Defense Health Agency.
- In August 2026, Emergent received a separate $24 million contract modification to supply CYFENDUS to BARDA.
- BioThrax is approved for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease in adults 18-65.
Financial Impact
Up to $22.3 million in total revenue from this modification, with $7.4 million in 2026 and the remainder in 2027.
Risk Factors
- Government contract awards are subject to budget appropriations and may not be renewed or expanded.
- The company's revenue concentration on U.S. government anthrax procurement creates single-customer dependency risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001367644-26-000116 |
| Document: a1142026biothraxmodpr.htm | 0001367644-26-000116 |
| Document: 0001367644-26-000116-index-headers.html | 0001367644-26-000116 |
| Document: 0001367644-26-000116-index.html | 0001367644-26-000116 |
| Document: 0001367644-26-000116.txt | 0001367644-26-000116 |
Track record
23 reports on EBS
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Viewing Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers